E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Classic Congenital Adrenal Hyperplasia |
|
E.1.1.1 | Medical condition in easily understood language |
CAH is a serious, chronically debilitating, and life-threatening genetic disorder characterized by impaired adrenal synthesis of cortisol and overproduction of adrenal androgens |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Genetic Phenomena [G05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010323 |
E.1.2 | Term | Congenital adrenal hyperplasia |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the proportion of subjects who can reduce GC use in subjects with CAH |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the percentage change in GC use in subjects with CAH -To evaluate the effect of tildacerfont in reducing the median cumulative HCe dose -To evaluate the effect of tildacerfont in reducing cardiovascular risk in subjects with CAH -To evaluate the effect of tildacerfont in improving homeostatic model assessment of insulin resistance (HOMA-IR) in subjects with CAH -To evaluate the effect of tildacerfont on body weight after 24 weeks in subjects with CAH -To evaluate the effect of tildacerfont on body weight after 52 weeks of tildacerfont treatment in subjects with CAH |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Male and female subjects ≥ 18 years old at screening 2.Has a known childhood diagnosis of classic CAH due to 21-hydroxylase deficiency based on genetic mutation in CYP21A2 and/or documented (at any time) elevated 17-OHP and currently treated with HC, HC acetate, prednisone, prednisolone, methylprednisolone (or a combinaton of the aforementionned GCs) 3.Has LLD ≤ A4 ≤ 2.5x ULN at screening measured before an am GC dose 4. Has been on a stable, supraphysiologic dose of GC replacement (defined as ≥30 mg/day and ≤60 mg/day in HCe) for ≥1 month before screening 5.For subjects with the salt-wasting form of CAH, subject has been on a stable dose of mineralocorticoid replacement for ≥1 month before screening 6. Follow contraception guidelines . Male subjects must also agree to refrain from donating sperm throughout the Treatment Period and for 90 days after the last dose of study drug. 7.Is able to understand all study procedures and risks involved and provides written informed consent indicating willingness to comply with all aspects of the protocol.
|
|
E.4 | Principal exclusion criteria |
1.Has a known or suspected diagnosis of any other known form of classic CAH (not due to 21 hydroxylase deficiency) 2.Has a history that includes bilateral adrenalectomy or hypopituitarism 3.Has a history of allergy or hypersensitivity to tildacerfont, any of its excipients, or any other CRF1 receptor antagonist 4.Shows clinical signs or symptoms of adrenal insufficiency 5.Has had a clinically significant unstable medical condition, medically significant illness, or chronic disease occurring within 30 days of screening, including but not limited to: a.An ongoing malignancy or <3 years of remission history from any malignancy, other than successfully treated localized skin cancer b.Estimated glomerular filtration rate (eGFR) of <45 mL/min/1.73 m2 c. Current or history of liver disease d. History of alcohol or substance abuse within the last year e. Active hepatitis B, C or HIV at screening f. subjects who plan to undergo bariatric surgery during the study are excluded g. any other condition that would impact subject safety or confound interpretation 6.Psychiatric conditions, including but not limited to bipolar disorder, schizophrenia, or schizoaffective disorders that are not effectively controlled on medication and may have an adverse impact on study compliance. Symptoms including hallucinations, delusions, and psychosis are exclusionary. Additionally: a. Increased risk of suicide based on the Investigator’s judgment or the results of the Columbia–Suicide Severity Rating Scale (C SSRS) conducted at screening and baseline (eg, C-SSRS Type 3, 4, or 5 ideation within the past 6 months or any suicidal behavior within the past 12 months) b. HADS score >12 for either depression or anxiety at screening or baseline 7.Has clinically significant abnormal ECG or clinical laboratory results. 8. Routinely works overnight shifts 9.Subjects with travel plans/work schedules that result in significant and frequent changes in time zones (>2 hours) will require Medical Monitor approval for enrollment. 10.Females who are pregnant or nursing 11.Use of any other investigational drug from 30 days or 5 half-lives (whichever is longer) before screening to the end of the study 12.Use of the following drugs from 30 days or 5 half-lives (whichever is longer) before the start of the Treatment Period to the end of the study a. Rosiglitazone, aromatase inhibitors, testosterone, or growth hormones, or any other medication or supplement that could impact subject safety or confound interpretation of study results b. The drugs listed in Section 13.1 13.Donation or receipt of blood from 90 days before Screening to the end of the study; donation or receipt of platelets, white blood cells, or plasma from 30 days before Screening to the end of the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of subjects with at least a 5mg/day HCe reduction from baseline in GC dose and A4 ≤ ULN at Week 24 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-Percent change from baseline in GC dose at Week 24 -Median total cumulative GC dose in HCe at Week 24 -Proportion of subjects with improvement in at least one cardiovascular risk factor at Week 24 -Change from baseline in the HOMA-IR at Week 24 -Percent change from baseline in body weight at Week 24 -Percent change from baseline in body weight after 52 weeks of tildacerfont treatment |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Optional open label extension study |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 21 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Switzerland |
Australia |
Brazil |
Canada |
Korea, Republic of |
United Kingdom |
United States |
Denmark |
Estonia |
Germany |
Ireland |
Italy |
Latvia |
Lithuania |
Netherlands |
Poland |
Romania |
Spain |
Sweden |
Türkiye |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A subject is considered to have completed study treatment if the subject has completed all visits through Week 76 of the Treatment Period. A subject is considered to have completed the study if the subject has completed all phases of the study, including the final follow-up visit. The end of the study is defined as the date of the last follow-up visit of the last subject in the study |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 3 |